{"id":5715,"date":"2018-07-02T15:27:29","date_gmt":"2018-07-02T13:27:29","guid":{"rendered":"http:\/\/wordpress.p545550.webspaceconfig.de\/uncategorized\/pieris-pharmaceuticals-beruft-dr-ann-barbier-in-den-aufsichtsrat\/"},"modified":"2020-06-29T13:35:52","modified_gmt":"2020-06-29T11:35:52","slug":"pieris-pharmaceuticals-beruft-dr-ann-barbier-in-den-aufsichtsrat","status":"publish","type":"post","link":"https:\/\/www.izb-online.de\/en\/pieris-pharmaceuticals-beruft-dr-ann-barbier-in-den-aufsichtsrat\/","title":{"rendered":"Pieris Pharmaceuticals appoints Dr. Ann Barbier to its Board of Directors"},"content":{"rendered":"

[vc_row el_class=”gco-magazine-container”][vc_column el_class=”bildspalte”][vc_row_inner][vc_column_inner offset=”vc_col-lg-12 vc_col-md-12″][vc_column_text el_class=”gco-magazine–title”]<\/p>\n

Pieris Pharmaceuticals appoints Dr. Ann Barbier to its Board of Directors<\/h1>\n

[\/vc_column_text][vc_column_text el_class=”gco-magazine–post-date”]July 2018[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine–quote”][vc_column_inner][vc_single_image image=”5708″ img_size=”155×155″ alignment=”center” style=”vc_box_circle_2″][vc_column_text el_class=”gco-magazine–picture-discription-blank”]Dr. Ann Barbier, Board of Directors, Pieris Pharmaceuticals, Inc.[\/vc_column_text][vc_column_text el_class=”gco-magazine-copyright-blank”]<\/p>\n

\u00a9 Pieris Pharmaceuticals Inc.<\/p>\n

[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner el_class=”gco-magazine-container–copy”][vc_column_inner][vc_column_text]Pieris Pharmaceuticals, Inc. announced that Dr. Ann Barbier has joined the Company\u2019s Board of Directors. Dr. Barbier is the Chief Medical Officer of Translate Bio. Prior to joining Translate Bio, Dr. Barbier was Vice President of Clinical Development, Rare Genetic Diseases, at Agios Pharmaceuticals, where she led the development program of a small molecule in rare benign hematological diseases. Previously, Dr. Barbier spent seven years at Shire, most recently as Global Clinical Development Lead and Senior Medical Director, where she worked on a variety of rare genetic diseases. Her prior experience includes positions at Envivo, Johnson & Johnson and Aventis. Dr. Barbier received her M.D. and Ph.D. in pharmacology from the University of Gent, Belgium, and a Master of Science from the Free University of Brussels, Belgium. She pursued a postdoctoral fellowship at the University of Tennessee in Memphis. Commenting on the announcement Dr. Barbier stated: \u201cI am thrilled to join the Board of Directors of Pieris at this exciting time for the Company. Pieris is in the midst of a rapid phase of growth, including ongoing clinical studies for three of its drug candidates in trials across the globe. I look forward to working with my fellow Directors and the Pieris management team to continue to advance the Company\u2019s proprietary and codevelopment programs into and through the clinic.\u201d[\/vc_column_text][vc_column_text]About Pieris Pharmaceuticals
\n<\/strong>Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-lifeoptimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin\u00ae is a registered trademark of Pieris.[\/vc_column_text][vc_column_text css=”.vc_custom_1583761043671{background-color: #1e73be !important;}” el_class=”redaktionell”][\/vc_column_text][\/vc_column_inner][\/vc_row_inner]\n\n

\n \n